Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beckmann

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Global Change Biology|March 26, 2019
Plasticity in elk migration timing is a response to changing environmental conditionsGregory J M Rickbeil, Jerod A Merkle, Greg Anderson, et al.
Oncotarget|February 21, 2020
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertibWayne D Blosser, Jack A Dempsey, Ann M McNulty, et al.
Cell Reports|March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeDavid A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Global Change Biology|March 26, 2019
Plasticity in elk migration timing is a response to changing environmental conditionsGregory J M Rickbeil, Jerod A Merkle, Greg Anderson, et al.
Oncotarget|February 21, 2020
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertibWayne D Blosser, Jack A Dempsey, Ann M McNulty, et al.
Cell Reports|March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeDavid A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor ModelsCaitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 9